Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Cerilliant
Dow
Julphar
Covington
Medtronic
Accenture
Argus Health
Harvard Business School

Generated: January 19, 2019

DrugPatentWatch Database Preview

BOEHRINGER INGELHEIM Company Profile

« Back to Dashboard

What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?

BOEHRINGER INGELHEIM has forty-eight approved drugs.

There are ninety-four US patents protecting BOEHRINGER INGELHEIM drugs. There is one tentative approval on BOEHRINGER INGELHEIM drugs.

There are two thousand three hundred and sixteen patent family members on BOEHRINGER INGELHEIM drugs in sixty-seven countries and one hundred and sixty-seven supplementary protection certificates in fifteen countries.

Drugs and US Patents for BOEHRINGER INGELHEIM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim SPIRIVA RESPIMAT tiotropium bromide SPRAY, METERED;INHALATION 021936-002 Sep 15, 2015 RX Yes No 7,396,341*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004 RX Yes Yes RE38912*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 RX Yes Yes 10,105,323 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for BOEHRINGER INGELHEIM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim SPIRIVA RESPIMAT tiotropium bromide SPRAY, METERED;INHALATION 021936-002 Sep 15, 2015 6,176,442 ➤ Try a Free Trial
Boehringer Ingelheim GLYXAMBI empagliflozin; linagliptin TABLET;ORAL 206073-002 Jan 30, 2015 6,303,661 ➤ Try a Free Trial
Boehringer Ingelheim VIRAMUNE nevirapine SUSPENSION;ORAL 020933-001 Sep 11, 1998 5,366,972*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 20 mg, 30 mg and 40 mg ➤ Subscribe 2017-07-12
➤ Subscribe Tablets 10 mg and 25 mg ➤ Subscribe 2018-08-01
➤ Subscribe Tablets 20 mg, 40 mg and 80 mg ➤ Subscribe 2006-12-26
➤ Subscribe Extended-release Capsules 25 mg and 200 mg ➤ Subscribe 2007-02-01
➤ Subscribe Tablets 80 mg/25 mg ➤ Subscribe 2009-02-27
➤ Subscribe Capsules eq. to 75 mg base and 150 mg base ➤ Subscribe 2014-10-20
➤ Subscribe Tablets 0.25 mg ➤ Subscribe 2005-05-27
➤ Subscribe Inhalation Powder Capsules 18 mcg ➤ Subscribe 2018-05-11
➤ Subscribe Tablets 5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg ➤ Subscribe 2018-08-01
➤ Subscribe Extended-releaseTablets 2.5 mg/1000 mg 5 mg/1000 mg ➤ Subscribe 2018-03-28
➤ Subscribe Extended-release Tablets 2.25 mg and 3.75 mg ➤ Subscribe 2011-07-26
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 2013-06-21
➤ Subscribe Tablets 10 mg/5 mg and 25 mg/5 mg ➤ Subscribe 2018-08-01
➤ Subscribe Tablets 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg ➤ Subscribe 2015-05-04
➤ Subscribe Tablets 80 mg/12.5 mg and 40 mg/12.5 mg ➤ Subscribe 2008-12-31
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2018-10-15
➤ Subscribe Tablets 0.125 mg, 0.5 mg, 1 mg and 1.5 mg ➤ Subscribe 2005-06-24
➤ Subscribe Capsules eq. to 110 mg base ➤ Subscribe 2015-12-15
➤ Subscribe Tablets 0.75 mg ➤ Subscribe 2008-07-31
➤ Subscribe Oral Suspension 7.5 mg/5 mL ➤ Subscribe 2009-12-17
➤ Subscribe Tablets 5 mg ➤ Subscribe 2015-05-04
➤ Subscribe Extended-release Tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg ➤ Subscribe 2010-06-01
➤ Subscribe Extended-release Tablets 5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg ➤ Subscribe 2018-08-01

Supplementary Protection Certificates for BOEHRINGER INGELHEIM Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0349 Netherlands ➤ Try a Free Trial 300349, 20180216, EXPIRES: 20230215
00216 Netherlands ➤ Try a Free Trial PRODUCT NAME: TIPRANAVIR, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
/1999 Austria ➤ Try a Free Trial PRODUCT NAME: TELMISARTAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; NAT. REGISTRATION NO/DATE: EU/1/98/089/001-010 19981211; FIRST REGISTRATION: BE K (1998) 4288-DE 19981211
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Accenture
US Department of Justice
Daiichi Sankyo
Argus Health
McKinsey
Cantor Fitzgerald
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.